Registry and Biosample Repository for Cancer and Benign Tumor Patients Undergoing Radiotherapy

What this Trial Is About

Researchers are establishing a registry and biosample repository for patients aged 18 and older who have been diagnosed with cancer or benign tumors and are undergoing radiotherapy. This observational study aims to collect and store biological samples such as blood, urine, and tumor specimens to support future research. The study is sponsored by the Abramson Cancer Center at Penn Medicine and focuses on understanding health outcomes related to radiotherapy treatment. Participants contribute samples and health information during their radiotherapy treatment period. The study does not involve treatment interventions but collects biosamples and clinical data to build a resource for ongoing and future cancer research. The repository will enable researchers to study various aspects of tumor biology and treatment effects over time. Throughout participation, individuals will undergo health assessments that are tracked for up to 10 years. The study involves no additional treatment procedures but focuses on long-term monitoring of health outcomes. This extended follow-up helps to better understand patient health after radiotherapy. Total participation duration may vary depending on individual follow-up timelines.

The Radiation Oncology Registry and Biosample Repository